Recipharm (RECI B)
Free
No email, no account, no signup.
Pulling latest news for Recipharm…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
NEUTRAL
Sentiment
7/10
Risk
6/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has improved modestly as the US capex signals demand and strategic focus in biologics/ATMP, but visibility in market data and social media remains low because the company is privately held.
Exchange
Nasdaq Stockholm
Type
Industrials
Sector
Pharmaceutical contract development and manufacturing (CDMO)
Market sentiment
Sentiment has improved modestly as the US capex signals demand and strategic focus in biologics/ATMP, but visibility in market data and social media remains low because the company is privately held.
Why NEUTRAL ?
- **REVIEW** because the company is **delisted** and cannot be bought directly on-exchange
- For exposure, **monitor a potential IPO/exit** or consider **indirect exposure via EQT**
- Operationally stable, but **biologics/ATMP execution** and macro remain key uncertainties
- No direct position possible; monitor IPO/exit 2026–2028 or indirect via EQT.
Recent News
- Since 5 June 2026, Recipharm has issued press releases covering (1) progress with Fusix Biotech on an oncolytic virus platform (8 June 2026) and (2) a multi-million investment in the US to expand sterile fill-and-finish capacity for biologics and advanced therapies (15 June 2026). The company remains private/delisted, limiting ongoing financial transparency.
Bull case
- **Portfolio streamlining/divestments** may sharpen focus on core growth areas
- **New biologics/ATMP contracts** could support the growth narrative
- **Capacity investments** (e.g., pre-filled syringes/lyo) can drive positive newsflow
Unlock to read more →
Bear case
- **No direct public equity upside** because the company is delisted
- **Macro/geopolitical uncertainty** may reduce customer R&D/clinical spend
- **Lower disclosure** as a private company increases uncertainty
Unlock to read more →
Catalysts
20 Aug 2026 — Q2 2026 update (calendar milestone)
Dilution Risk
Assessment: Low
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Recipharm – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.